Chikungunya Vaccine Candidates: Current Landscape and Future Prospects

Chikungunya virus (CHIKV) is an alphavirus that has spread globally in the last twenty years. Although mortality is rather low, infection can result in debilitating arthralgia that can persist for years. Unfortunately, no treatments or preventive vaccines are currently licensed against CHIKV infections. However, a large range of promising preclinical and clinical vaccine candidates have been developed during recent years. This review will give an introduction into the biology of CHIKV and the immune responses that are induced by infection, and will summarize CHIKV vaccine development.

Automated summary

CHIKV is a virus that has spread globally in the last twenty years. Although mortality is low, infection can result in long-term joint pain. Currently, there are no licensed treatments or preventive vaccines against CHIKV infections. However, there have been promising vaccine candidates developed in recent years.